ONO-7913 Phase I Study (ONO-7913)

Summary

To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.

Timeline

Start

2020-07-28

Primary completion

2022-01-13

Completion

2022-01-13

Publications

• Koyama T, Shimizu T, Kondo S, Katsuya Y, Sudo K, Yoshida T, Yonemori K, Matsumoto K, Yamamoto N. Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study. BMC Res Notes. 2026 Mar 26;19(1):203. doi: 10.1186/s13104-026-07787-6.

Drugs

Indications